Genprex To Present Data On The Use Of REQORSA For The Treatment Of Lung Cancers At 2023 2023 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Genprex will present data on the use of REQORSA for the treatment of lung cancers at the 2023 AACR-NCI-EORTC International Conference. The Acclaim-1 Phase 1 study showed no Dose Limiting Toxicity and established the Phase 2 Recommended Dose. The results also showed the efficacy of REQORSA in combination with Tagrisso. Preclinical results showed that REQORSA in combination with a checkpoint inhibitor has anti-tumor activity in a humanized mouse model of small cell lung cancer.
October 04, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genprex will present positive data on the use of REQORSA for the treatment of lung cancers, which could potentially boost investor confidence in the company.
The positive data on REQORSA, a product of Genprex, could potentially boost the company's stock as it shows progress in the company's research and development efforts. The absence of Dose Limiting Toxicity and the efficacy of REQORSA in combination with other drugs could be seen as a positive development by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100